Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An update on iron chelation therapy.

Literature DB >> 22790257

An update on iron chelation therapy.

Erika Poggiali¹, Elena Cassinerio, Laura Zanaboni, Maria Domenica Cappellini.

Abstract

Entities: Chemical

Mesh：

Substances：
Iron

Year: 2012 PMID： 22790257 PMCID： PMC3496216 DOI： 10.2450/2012.0008-12

Source DB: PubMed Journal: Blood Transfus ISSN： 1723-2007 Impact factor: 3.443

× No keyword cloud information.

91 in total

Review 1. Secondary iron overload.

Authors: J P Kushner; J P Porter; N F Olivieri
Journal: Hematology Am Soc Hematol Educ Program Date: 2001

2. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Authors: Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Arnold Ganser; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Gabor Domokos; Bernard Roubert; Christian Rose
Journal: Leuk Res Date: 2010-05-06 Impact factor: 3.156

3. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.

Authors: Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal: Haematologica Date: 2010-11-11 Impact factor: 9.941

4. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

Authors: Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Amal El-Beshlawy; Lee Lee Chan; Yesim Aydinok; Mohsen Saleh Elalfy; Pranee Sutcharitchan; Chi-Kong Li; Hishamshah Ibrahim; Vip Viprakasit; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal: Blood Date: 2009-12-08 Impact factor: 22.113

5. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors: Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal: Transl Res Date: 2010-05-27 Impact factor: 7.012

6. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.

Authors: G Link; A M Konijn; W Breuer; Z I Cabantchik; C Hershko
Journal: J Lab Clin Med Date: 2001-08

7. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Authors: M Domenica Cappellini; Mohamed Bejaoui; Leyla Agaoglu; Duran Canatan; Marcello Capra; Alan Cohen; Guillermo Drelichman; Marina Economou; Slaheddine Fattoum; Antonis Kattamis; Yurdanur Kilinc; Silverio Perrotta; Antonio Piga; John B Porter; Louis Griffel; Victor Dong; Joan Clark; Yesim Aydinok
Journal: Blood Date: 2011-05-31 Impact factor: 22.113

8. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.

Authors: M H Miceli; L Dong; M L Grazziutti; A Fassas; R Thertulien; F Van Rhee; B Barlogie; E J Anaissie
Journal: Bone Marrow Transplant Date: 2006-05 Impact factor: 5.483

Review 9. Iron chelation beyond transfusion iron overload.

Authors: Antonello Pietrangelo
Journal: Am J Hematol Date: 2007-12 Impact factor: 10.047

10. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.

Authors: Vasilios Berdoukas; Giorgos Chouliaras; Panagiotis Moraitis; Kirykos Zannikos; Eleni Berdoussi; Vassilios Ladis
Journal: J Cardiovasc Magn Reson Date: 2009-06-28 Impact factor: 5.364

66 in total

1. Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

Authors: Matteo Molica; Adriano Salaroli; Giuliana Alimena; Massimo Breccia
Journal: Blood Transfus Date: 2013-04-15 Impact factor: 3.443

2. Free iron status & insulin resistance in type 2 diabetes mellitus: Analyzing the probable role of a peanut protein.

Authors: Souvik Sen; Sumanta Kumar Ghatak; Dipanjali Majumdar; Kamalika Sen; Basudev Bhattacharya
Journal: Indian J Med Res Date: 2015-11 Impact factor: 2.375

Review 3. 2015 Clinical trials update in sickle cell anemia.

Authors: Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal: Am J Hematol Date: 2015-10 Impact factor: 10.047

4. Multifunctional Polymeric Micelles for Combining Chelation and Detection of Iron in Living Cells.

Authors: Zhi Liu; Max Purro; Jing Qiao; May P Xiong
Journal: Adv Healthc Mater Date: 2017-06-29 Impact factor: 9.933

5. Combating iron overload: a case for deferoxamine-based nanochelators.

Authors: Gregory Jones; Sumanta Kumar Goswami; Homan Kang; Hak Soo Choi; Jonghan Kim
Journal: Nanomedicine (Lond) Date: 2020-05-20 Impact factor: 5.307

6. Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate.

Authors: Giovanna Rassu; Elena Soddu; Massimo Cossu; Antonio Brundu; Guido Cerri; Nicola Marchetti; Luca Ferraro; Raymond F Regan; Paolo Giunchedi; Elisabetta Gavini; Alessandro Dalpiaz
Journal: J Control Release Date: 2015-01-22 Impact factor: 9.776